Products for Research Use Only
RegisterLogin

Ceftriaxone

CAT: 0804-HY-B0712-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0712-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].
CAS Number
73384-59-5
Product Name Alternative
Ro 13-9904 (free acid)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Aurora Kinase; Bacterial; GSK-3
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection; Neurological Disease; Inflammation/Immunology; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ceftriaxone.html
Concentration
10mM
Purity
99.62
Solubility
DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C(N12)=C(CSC(N(C)NC3=O)=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O
Molecular Formula
C18H18N8O7S3
Molecular Weight
554.58
Precautions
H302, H315, H319, H335
References & Citations
[1]Nahata MC, et al. Ceftriaxone: a third-generation cephalosporin. Drug Intell Clin Pharm. 1985 Dec;19 (12) :900-6.|[2] Nassar H, et al. Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors. RSC Adv. 2023 Apr 11;13 (17) :11278-11290.|[3]Zhang Y, et al. Ceftriaxone Protects Astrocytes from MPP (+) via Suppression of NF-κB/JNK/c-Jun Signaling. Mol Neurobiol. 2015 Aug;52 (1) :78-92.|[4]Li X, et al. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. Carcinogenesis. 2012 Dec;33 (12) :2548-57.|[5]Hakimizadeh E, et al. Ceftriaxone improves hepatorenal damages in mice subjected to D-galactose-induced aging. Life Sci. 2020 Oct 1;258:118119.|[6]Uyanikgil Y, et al. Positive effects of ceftriaxone on pentylenetetrazol-induced convulsion model in rats. Int J Neurosci. 2016;126 (1) :70-5.|[7]Gunduz O, et al. Anti-allodynic and anti-hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. Neurosci Lett. 2011 Mar 10;491 (1) :23-5.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
β-lactam
Citation 01
AMB Express. 2024 Dec 24;14 (1) :141.|BMC Cancer. 2025 Jun 1;25 (1) :977.|BMC Microbiol. 2025 Apr 29;25 (1) :257.|Diagn Microbiol Infect Dis. 2025 Nov 4;114 (2) :117181.|EBioMedicine. 2022 Apr;78:103943.|Proc Natl Acad Sci U S A. 2025 Dec 2;122 (48) :e2524436122.|Cell Chem Biol. 2024 May 20:S2451-9456 (24) 00179-X.|Chemosphere. 2023 Dec:344:140353.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|Microbiol Spectr. 2025 Oct 16:e0160325.|Nat Commun. 2022 Mar 2;13 (1) :1116.

Alternative Products

CatalogName
T75295-01Ceftriaxone
RM-C062401-01Ceftriaxone EP Impurity A ((E) -Ceftriaxone)
C39SD1057Ceftriaxone/Tazobactam

Popular Products